|
US7270971B2
(en)
*
|
2003-10-16 |
2007-09-18 |
Merck & Co., Inc. |
Fluorescence assay for measuring the rate of cholesterol ester transfer
|
|
DOP2005000123A
(es)
*
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
CN101212966B
(zh)
*
|
2005-07-01 |
2012-03-14 |
默沙东公司 |
合成cetp抑制剂的方法
|
|
WO2007067593A2
(en)
*
|
2005-12-05 |
2007-06-14 |
Merck & Co., Inc. |
Self-emulsifyng formulations of cetp inhibitors
|
|
AR057218A1
(es)
*
|
2005-12-15 |
2007-11-21 |
Astra Ab |
Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
|
|
JP5199121B2
(ja)
*
|
2005-12-30 |
2013-05-15 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｅｔｐ阻害剤
|
|
JP5229567B2
(ja)
*
|
2005-12-30 |
2013-07-03 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｃｅｔｐ阻害剤
|
|
CN101365689A
(zh)
|
2005-12-30 |
2009-02-11 |
默克公司 |
作为cetp抑制剂的1,3－唑烷－2－酮衍生物
|
|
WO2007081570A2
(en)
*
|
2005-12-30 |
2007-07-19 |
Merck & Co., Inc. |
Cholesteryl ester transfer protein inhibitors
|
|
BRPI0707584A2
(pt)
*
|
2006-02-09 |
2011-05-10 |
Merck & Co Inc |
composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
|
|
US8383660B2
(en)
*
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
*
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2007136672A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Merck & Co., Inc. |
Synthesis of a biaryl synthetic intermediate
|
|
WO2008082567A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Merck & Co., Inc. |
Process for synthesizing a cetp inhibitor
|
|
NZ578296A
(en)
|
2007-01-26 |
2012-07-27 |
Kaneq Pharma Inc |
Fused aromatic ptp-1b inhibitors
|
|
WO2008115442A1
(en)
|
2007-03-16 |
2008-09-25 |
Concert Pharmceuticals, Inc. |
Inhibitors of cholesterol ester transfer protein
|
|
CA2688187C
(en)
|
2007-05-07 |
2016-10-11 |
Merck & Co., Inc. |
Method of treament using fused aromatic compounds having anti-diabetic activity
|
|
EP2532643A1
(en)
|
2007-06-08 |
2012-12-12 |
MannKind Corporation |
IRE-1A Inhibitors
|
|
AU2008266956A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
CETP inhibitors derived from benzoxazole arylamides
|
|
EP2170058B1
(en)
*
|
2007-06-20 |
2013-07-03 |
Merck Sharp & Dohme Corp. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
WO2008156718A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Merck & Co., Inc. |
Cetp inhibitors derived from benzoxazole arylamides
|
|
BRPI0814403A2
(pt)
|
2007-07-02 |
2015-01-27 |
Hoffmann La Roche |
Devirados de imidazol como antagonistas de receptor ccr2
|
|
AR067673A1
(es)
*
|
2007-07-26 |
2009-10-21 |
Vitae Pharmaceuticals Inc |
Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
|
|
AR069207A1
(es)
*
|
2007-11-07 |
2010-01-06 |
Vitae Pharmaceuticals Inc |
Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
|
|
US8440658B2
(en)
|
2007-12-11 |
2013-05-14 |
Vitae Pharmaceuticals, Inc. |
Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
|
|
TW200934490A
(en)
*
|
2008-01-07 |
2009-08-16 |
Vitae Pharmaceuticals Inc |
Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
|
|
JP5490020B2
(ja)
*
|
2008-01-24 |
2014-05-14 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
|
|
EP2245002A4
(en)
*
|
2008-02-01 |
2011-08-17 |
Amira Pharmaceuticals Inc |
AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN
|
|
US8067445B2
(en)
|
2008-02-01 |
2011-11-29 |
Panmira Pharmaceuticals, Llc |
N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
|
|
EP2252598A2
(en)
*
|
2008-02-11 |
2010-11-24 |
Vitae Pharmaceuticals, Inc. |
1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8242145B2
(en)
|
2008-02-14 |
2012-08-14 |
Panmira Pharmaceuticals, Llc |
Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
|
|
WO2009102460A2
(en)
*
|
2008-02-15 |
2009-08-20 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
JP2011513242A
(ja)
|
2008-02-25 |
2011-04-28 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体アンタゴニスト
|
|
JP5538356B2
(ja)
*
|
2008-03-18 |
2014-07-02 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
|
|
JP2011518130A
(ja)
|
2008-04-02 |
2011-06-23 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
|
|
WO2009134392A1
(en)
|
2008-05-01 |
2009-11-05 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
MX2010011935A
(es)
|
2008-05-01 |
2011-05-19 |
Vitae Pharmaceuticals Inc |
Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1.
|
|
WO2009134387A1
(en)
|
2008-05-01 |
2009-11-05 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
US8063088B2
(en)
*
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
|
NZ590495A
(en)
|
2008-07-25 |
2012-10-26 |
Vitae Pharmaceuticals Inc |
Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
|
EP2324017B1
(en)
|
2008-07-25 |
2014-12-31 |
Boehringer Ingelheim International GmbH |
INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
|
|
WO2010010150A1
(en)
|
2008-07-25 |
2010-01-28 |
Boehringer Ingelheim International Gmbh |
Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
|
|
GB2463788B
(en)
|
2008-09-29 |
2010-12-15 |
Amira Pharmaceuticals Inc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
DE102008049675A1
(de)
|
2008-09-30 |
2010-04-01 |
Markus Dr. Heinrich |
Verfahren zur Herstellung von 3-Aminobiphenylen
|
|
US8378107B2
(en)
|
2008-10-01 |
2013-02-19 |
Panmira Pharmaceuticals, Llc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
EP2348859B1
(en)
*
|
2008-10-01 |
2013-12-04 |
Merck Sharp & Dohme Corp. |
Prodrugs of oxazolidinone cetp inhibitors
|
|
WO2010042652A2
(en)
|
2008-10-08 |
2010-04-15 |
Amira Pharmaceuticals, Inc. |
Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
|
|
AU2009307884B2
(en)
|
2008-10-22 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
CN102271509A
(zh)
|
2008-10-31 |
2011-12-07 |
默沙东公司 |
用于抗糖尿病药的新型环苯并咪唑衍生物
|
|
WO2010057118A2
(en)
|
2008-11-17 |
2010-05-20 |
Amira Pharmaceuticals, Inc. |
Heterocyclic antagonists of prostaglandin d2 receptors
|
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
WO2010085528A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
|
WO2010085525A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
JP5679997B2
(ja)
|
2009-02-04 |
2015-03-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
|
|
WO2010091176A1
(en)
|
2009-02-05 |
2010-08-12 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
|
UA109255C2
(ru)
|
2009-04-30 |
2015-08-10 |
Берінгер Інгельхайм Інтернешнл Гмбх |
Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
|
|
EP2440537A1
(en)
|
2009-06-11 |
2012-04-18 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
|
|
US8883778B2
(en)
|
2009-07-01 |
2014-11-11 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
|
|
KR20120047273A
(ko)
*
|
2009-08-05 |
2012-05-11 |
판미라 파마슈티칼스, 엘엘씨 |
Ｄｐ2 길항제 및 이의 용도
|
|
JP2011057661A
(ja)
|
2009-08-14 |
2011-03-24 |
Bayer Cropscience Ag |
殺虫性カルボキサミド類
|
|
WO2011056737A1
(en)
|
2009-11-05 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Novel chiral phosphorus ligands
|
|
WO2011088025A1
(en)
|
2010-01-15 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US8648192B2
(en)
|
2010-05-26 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
|
|
EP2397473A1
(en)
|
2010-06-14 |
2011-12-21 |
LEK Pharmaceuticals d.d. |
A stable highly crystalline anacetrapib
|
|
WO2011159760A1
(en)
|
2010-06-16 |
2011-12-22 |
Vitae Pharmaceuticals, Inc. |
Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
|
|
EP2585444B1
(en)
|
2010-06-25 |
2014-10-22 |
Boehringer Ingelheim International GmbH |
Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
|
|
US20130225618A1
(en)
|
2010-10-04 |
2013-08-29 |
Kowa Co., Ltd. |
Agent for inhibiting expression of lipid metabolism related mrna
|
|
JP5852662B2
(ja)
*
|
2010-10-29 |
2016-02-03 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
環状アミン置換されたオキサゾリジノン系ｃｅｔｐ阻害薬
|
|
EA201300522A1
(ru)
|
2010-11-02 |
2013-11-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтические комбинации для лечения метаболических нарушений
|
|
EP2468736A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
EP2468735A1
(en)
|
2010-12-23 |
2012-06-27 |
LEK Pharmaceuticals d.d. |
Synthesis of intermediates for preparing anacetrapib and derivates thereof
|
|
WO2012101142A1
(en)
|
2011-01-26 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for assessing a subject's risk of having a cardiovascular disease.
|
|
CN103476258B
(zh)
|
2011-02-25 |
2017-04-26 |
默沙东公司 |
用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
|
|
BR112013026280A2
(pt)
*
|
2011-04-12 |
2024-04-30 |
Chong Kun Dang Pharmaceutical Corp |
Derivados de cicloalquenil arila para inibidor da cetp
|
|
US9345681B2
(en)
|
2011-07-07 |
2016-05-24 |
Mochida Pharmaceutical Co., Ltd. |
Anti-obesity agent comprising high-purity EPA
|
|
ES2683350T3
(es)
|
2011-07-08 |
2018-09-26 |
Novartis Ag |
Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
|
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
|
US9145348B2
(en)
*
|
2011-10-31 |
2015-09-29 |
Merck Sharpe & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
|
WO2013064188A1
(en)
|
2011-11-03 |
2013-05-10 |
Lek Pharmaceuticals D.D. |
A stable highly crystalline anacetrapib
|
|
EP2789347A4
(en)
|
2011-11-29 |
2015-12-16 |
Kowa Co |
MEANS TO INHIBIT THE EXPRESSION OF NPC1L1 AND / OR LIPG-MRNA AND MEDICAMENTS FOR THE PREVENTION AND / OR TREATMENT OF ADIPOSITAS
|
|
WO2013081373A1
(en)
|
2011-11-30 |
2013-06-06 |
Daewoong Pharmaceutical Co., Ltd. |
Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases
|
|
WO2013091696A1
(en)
|
2011-12-21 |
2013-06-27 |
Lek Pharmaceuticals D.D. |
Synthesis of intermediates for preparing anacetrapib and derivatives thereof
|
|
WO2013165854A1
(en)
*
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Cyclic amine substituted heterocyclic cetp inhibitors
|
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
|
WO2014012428A1
(zh)
*
|
2012-07-19 |
2014-01-23 |
上海恒瑞医药有限公司 |
噁唑烷酮类衍生物、其制备方法及其在医药上的应用
|
|
EP2888006B1
(en)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators
|
|
EP2934518B1
(en)
|
2012-12-19 |
2020-02-19 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
|
WO2014099834A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Therapeutic thiazolidinone compounds
|
|
WO2014111953A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited |
Process for preparation of anacetrapib and intermediates thereof
|
|
JP6166385B2
(ja)
*
|
2013-01-31 |
2017-07-19 |
チョン クン ダン ファーマシューティカル コーポレーション |
コレステロールエステル転送蛋白質（ｃｅｔｐ）抑制剤としてのビアリールまたは複素環式ビアリール置換シクロヘキセン誘導体化合物
|
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
US9981970B2
(en)
|
2013-07-30 |
2018-05-29 |
Merck Sharp & Dohme Corp. |
Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors
|
|
US9688630B2
(en)
|
2013-10-10 |
2017-06-27 |
Merck Sharp & Dohme Corp. |
3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
|
|
WO2015094932A1
(en)
|
2013-12-17 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
WO2015106674A1
(zh)
*
|
2014-01-14 |
2015-07-23 |
杭州普晒医药科技有限公司 |
一种安塞曲匹的晶型及其制备方法、其药物组合物和用途
|
|
CN103923030B
(zh)
*
|
2014-03-27 |
2015-07-22 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的关键中间体的合成方法
|
|
CN103923031A
(zh)
*
|
2014-04-01 |
2014-07-16 |
汕头经济特区鮀滨制药厂 |
一种安塞曲匹的中间体的合成方法
|
|
WO2016018729A1
(en)
*
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
|
PT3174995T
(pt)
|
2014-07-30 |
2020-10-15 |
Hoffmann La Roche |
Marcadores genéticos para prever o tipo de resposta ao tratamento com um fármaco de aumento do hdl ou mimetizador do hdl
|
|
CN104230835B
(zh)
*
|
2014-09-01 |
2017-01-25 |
福建师范大学 |
一种合成n‑苯乙烯基恶唑烷‑2‑酮衍生物的方法
|
|
WO2016067194A1
(en)
*
|
2014-10-27 |
2016-05-06 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of anacetrapib and an intermediate thereof
|
|
CN106032362B
(zh)
*
|
2015-03-10 |
2018-06-19 |
湖南千金湘江药业股份有限公司 |
安塞曲匹的制备方法
|
|
KR20190020343A
(ko)
|
2016-06-29 |
2019-02-28 |
오리온 코포레이션 |
벤조디옥산 유도체 및 이의 약제학적 용도
|
|
WO2018016743A1
(ko)
*
|
2016-07-19 |
2018-01-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
|
|
US10851059B2
(en)
*
|
2016-08-17 |
2020-12-01 |
Novartis Ag |
Processes and intermediates for NEP inhibitor synthesis
|
|
CN106496154A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
安塞曲匹的制备方法
|
|
CN106496211A
(zh)
*
|
2016-10-18 |
2017-03-15 |
湖南德魅信息技术有限公司 |
二氟甲基取代的噁唑烷酮化合物及其用途
|
|
CN106749075A
(zh)
*
|
2016-11-24 |
2017-05-31 |
山东新华制药股份有限公司 |
阿那曲波的恶唑烷酮中间体的晶型及其制备方法
|
|
US20190070178A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
JP2021534236A
(ja)
|
2018-08-09 |
2021-12-09 |
ダルコア ファーマ ユーケー リミテッド，レザーヘッド，ツーク ブランチ |
新規発症２型糖尿病の発生遅延並びに２型糖尿病の進行緩徐化及び治療の方法
|
|
KR20210137442A
(ko)
|
2019-03-07 |
2021-11-17 |
달코어 파마 유케이 리미티드 레더헤드 저그 브랜치 |
심부전을 치료 또는 예방하고 심부전의 위험을 감소시키는 방법
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
EP4471042A3
(en)
|
2019-07-19 |
2025-03-05 |
Biosynth AG |
Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
|
|
WO2021226269A1
(en)
|
2020-05-05 |
2021-11-11 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|
|
MX2022013657A
(es)
|
2020-05-05 |
2023-02-01 |
Nuvalent Inc |
Quimioterápicos de éter macrocíclico heteroaromático.
|
|
KR102651062B1
(ko)
*
|
2020-10-08 |
2024-03-25 |
재단법인 대구경북첨단의료산업진흥재단 |
Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물
|
|
US20240360103A1
(en)
*
|
2021-06-30 |
2024-10-31 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
EP4408844A1
(en)
|
2021-10-01 |
2024-08-07 |
Nuvalent, Inc. |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
|
WO2025093129A1
(en)
|
2023-11-01 |
2025-05-08 |
Newamsterdam Pharma B.V. |
Treatment and prevention of age-related macular degeneration using a cetp inhibitor
|